{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:31:21Z","timestamp":1792071081868,"version":"4.4.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-01974-0","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T13:05:05Z","timestamp":1771074305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma ATN biomarkers across the alzheimer\u2019s disease continuum in a Chilean community- and clinic-based cohort"],"prefix":"10.1186","volume":"18","author":[{"given":"Paulina","family":"Orellana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Henr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Cabral-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela C L","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Bellaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Caviedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gonzalez-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickole","family":"Marin-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Damm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gonzalez-Billault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Thumala-Dockendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roque","family":"Villagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"de la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick","family":"A Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Duran-Aniotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Slachevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"6","key":"1974_CR1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1515\/cclm-2023-1434","volume":"62","author":"B Arslan","year":"2024","unstructured":"Arslan B, Zetterberg H, Ashton NJ. Blood-based biomarkers in Alzheimer\u2019s disease - moving towards a new era of diagnostics. Clin Chem Lab Med. 2024;62(6):1063\u20139.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"1974_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/alz.12757","volume":"19","author":"MA Parra","year":"2023","unstructured":"Parra MA, Orellana P, Leon T, Victoria CG, Henriquez F, Gomez R, et al. Biomarkers for dementia in Latin American countries: gaps and opportunities. Alzheimers Dement. 2023;19(2):721\u201335.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1974_CR3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"1974_CR4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer disease as a Clinical-Biological Construct-An international working group recommendation. JAMA Neurol. 2024;81(12):1304\u201311.","journal-title":"JAMA Neurol"},{"issue":"7","key":"1974_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Suarez-Calvet M, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Rev Neurol. 2024;20(7):426\u201339.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"1974_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(24)00132-6","volume":"5","author":"E McGlinchey","year":"2024","unstructured":"McGlinchey E, Duran-Aniotz C, Akinyemi R, Arshad F, Zimmer ER, Cho H, et al. Biomarkers of neurodegeneration across the Global South. Lancet Healthy Longev. 2024;5(10):100616.","journal-title":"Lancet Healthy Longev"},{"issue":"3","key":"1974_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1974_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"F Jessen","year":"2020","unstructured":"Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19(3):271\u20138.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1974_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342.","journal-title":"Nat Med"},{"issue":"4","key":"1974_CR10","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Dore V, et al. Plasma Abeta42\/40 ratio, p-tau181, GFAP, and NfL across the alzheimer\u2019s disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023;19(4):1117\u201334.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1974_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging. 2021;1(1):114\u201323.","journal-title":"Nat Aging"},{"issue":"24","key":"1974_CR12","doi-asserted-by":"publisher","first-page":"e3280","DOI":"10.1212\/WNL.0000000000010951","volume":"95","author":"MA Bock","year":"2020","unstructured":"Bock MA, Bahorik A, Brenowitz WD, Yaffe K. Apathy and risk of probable incident dementia among community-dwelling older adults. Neurology. 2020;95(24):e3280\u20137.","journal-title":"Neurology"},{"key":"1974_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2022.104809","volume":"104","author":"J Shin","year":"2023","unstructured":"Shin J, Cho E. Patterns and risk factors of cognitive decline among community-dwelling older adults in South Korea. Arch Gerontol Geriatr. 2023;104:104809.","journal-title":"Arch Gerontol Geriatr"},{"issue":"4","key":"1974_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/alz.12227","volume":"17","author":"JJ Llibre-Guerra","year":"2021","unstructured":"Llibre-Guerra JJ, Li Y, Allegri RF, Mendez PC, Surace EI, Llibre-Rodriguez JJ, et al. Dominantly inherited alzheimer\u2019s disease in Latin america: genetic heterogeneity and clinical phenotypes. Alzheimers Dement. 2021;17(4):653\u201364.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1974_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13195-022-01052-1","volume":"14","author":"LT Takada","year":"2022","unstructured":"Takada LT, Alaez-Verson C, Burgute BD, Nitrini R, Sosa AL, Castilhos RM, et al. Discovery and validation of dominantly inherited alzheimer\u2019s disease mutations in populations from Latin America. Alzheimers Res Ther. 2022;14(1):108.","journal-title":"Alzheimers Res Ther"},{"key":"1974_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00221","volume":"9","author":"N Custodio","year":"2017","unstructured":"Custodio N, Wheelock A, Thumala D, Slachevsky A. Dementia in Latin America: epidemiological evidence and implications for public policy. Front Aging Neurosci. 2017;9:221.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1974_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/JAD-230231","volume":"94","author":"AG Garrido-Dzib","year":"2023","unstructured":"Garrido-Dzib AG, Chavez-Loria G, Magallon-Zertuche V, Avila-Nava A, Palacios-Gonzalez B, Gutierrez-Solis AL. Micro- and macronutrient intake and food group frequency consumed by subjects with cognitive impairment and dementia in Latin america: a systematic review. J Alzheimers Dis. 2023;94(2):425\u201339.","journal-title":"J Alzheimers Dis"},{"key":"1974_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.684524","volume":"12","author":"NV Dos Santos","year":"2021","unstructured":"Dos Santos NV, Yariwake VY, Marques KDV, Veras MM, Fajersztajn L. Air pollution: a neglected risk factor for dementia in Latin America and the Caribbean. Front Neurol. 2021;12:684524.","journal-title":"Front Neurol"},{"issue":"10","key":"1974_CR19","doi-asserted-by":"publisher","first-page":"e1600","DOI":"10.1016\/S2214-109X(24)00275-4","volume":"12","author":"RS Paradela","year":"2024","unstructured":"Paradela RS, Calandri I, Castro NP, Garat E, Delgado C, Crivelli L, et al. Population attributable fractions for risk factors for dementia in seven Latin American countries: an analysis using cross-sectional survey data. Lancet Glob Health. 2024;12(10):e1600\u201310.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"1974_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3233\/JAD-161261","volume":"58","author":"IE Vega","year":"2017","unstructured":"Vega IE, Cabrera LY, Wygant CM, Velez-Ortiz D, Counts SE. Alzheimer\u2019s disease in the Latino community: intersection of genetics and social determinants of health. J Alzheimers Dis. 2017;58(4):979\u201392.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1974_CR21","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/alz.13518","volume":"20","author":"WS Brum","year":"2024","unstructured":"Brum WS, Ashton NJ, Simren J, di Molfetta G, Karikari TK, Benedet AL, et al. Biological variation estimates of alzheimer\u2019s disease plasma biomarkers in healthy individuals. Alzheimers Dement. 2024;20(2):1284\u201397.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1974_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403\u201314.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1974_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13195-020-00711-5","volume":"12","author":"CM Calvin","year":"2020","unstructured":"Calvin CM, de Boer C, Raymont V, Gallacher J, Koychev I. European prevention of alzheimer\u2019s dementia C. Prediction of alzheimer\u2019s disease biomarker status defined by the \u2018ATN framework\u2019 among cognitively healthy individuals: results from the EPAD longitudinal cohort study. Alzheimers Res Ther. 2020;12(1):143.","journal-title":"Alzheimers Res Ther"},{"key":"1974_CR24","doi-asserted-by":"crossref","unstructured":"Toniolo S, Di Lorenzo F, Bernardini S, Mercuri NB, Sancesario GM. Blood-Brain barrier dysfunction and Abeta42\/40 ratio Dose-Dependent modulation with the ApoE genotype within the ATN framework. Int J Mol Sci. 2023;24(15):12151.","DOI":"10.3390\/ijms241512151"},{"key":"1974_CR25","doi-asserted-by":"publisher","first-page":"963845","DOI":"10.3389\/fnagi.2022.963845","volume":"14","author":"Q Sun","year":"2022","unstructured":"Sun Q, Ni J, Wei M, Long S, Li T, Fan D, et al. Plasma beta-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable alzheimer\u2019s disease dementia in Chinese individuals. Front Aging Neurosci. 2022;14:963845.","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"1974_CR26","doi-asserted-by":"publisher","first-page":"e2235068","DOI":"10.1001\/jamanetworkopen.2022.35068","volume":"5","author":"I Hajjar","year":"2022","unstructured":"Hajjar I, Yang Z, Okafor M, Liu C, Waligorska T, Goldstein FC, et al. Association of plasma and cerebrospinal fluid Alzheimer disease biomarkers with race and the role of genetic ancestry, vascular comorbidities, and neighborhood factors. JAMA Netw Open. 2022;5(10):e2235068.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1974_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10654-023-00988-4","volume":"38","author":"R Dong","year":"2023","unstructured":"Dong R, Denier-Fields DN, Van Hulle CA, Kollmorgen G, Suridjan I, Wild N, et al. Identification of plasma metabolites associated with modifiable risk factors and endophenotypes reflecting Alzheimer\u2019s disease pathology. Eur J Epidemiol. 2023;38(5):559\u201371.","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"1974_CR28","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.1002\/alz.14289","volume":"20","author":"N Custodio","year":"2024","unstructured":"Custodio N, Allegri R, Lopera F, Caramelli P. Need to adapt Alzheimer\u2019s disease criteria in Latin America. Alzheimers Dement. 2024;20(11):8206\u20138.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1974_CR29","volume":"14","author":"SE O'Bryant","year":"2022","unstructured":"O\u2019Bryant SE, Zhang F, Petersen M, Hall J, Johnson LA, Yaffe K, et al. Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: a Health & Aging Brain among Latino Elders (HABLE) study. Alzheimers Dement Diagn Assess Dis Monit. 2022;14(1):e12267.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"1","key":"1974_CR30","doi-asserted-by":"publisher","first-page":"e12202","DOI":"10.1002\/dad2.12202","volume":"13","author":"SE O\u2019Bryant","year":"2021","unstructured":"O\u2019Bryant SE, Johnson LA, Barber RC, Braskie MN, Christian B, Hall JR, et al. The health & aging brain among Latino elders (HABLE) study methods and participant characteristics. Alzheimers Dement (Amst). 2021;13(1):e12202.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"1974_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01655-w","volume":"17","author":"N Pandey","year":"2025","unstructured":"Pandey N, Yang Z, Cieza B, Reyes-Dumeyer D, Kang MS, Montesinos R, et al. Plasma phospho-tau217 as a predictive biomarker for Alzheimer\u2019s disease in a large south American cohort. Alzheimers Res Ther. 2025;17(1):1.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1974_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56756-3","volume":"16","author":"LE Santos","year":"2025","unstructured":"Santos LE, Mattos P, Pinheiro TL, Silva A, Drummond C, Sudo FK, et al. Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort. Nat Commun. 2025;16(1):2911.","journal-title":"Nat Commun"},{"issue":"4","key":"1974_CR33","doi-asserted-by":"publisher","first-page":"e238214","DOI":"10.1001\/jamanetworkopen.2023.8214","volume":"6","author":"LS Honig","year":"2023","unstructured":"Honig LS, Kang MS, Lee AJ, Reyes-Dumeyer D, Piriz A, Soriano B, et al. Evaluation of plasma biomarkers for A\/T\/N classification of Alzheimer disease among adults of Caribbean Hispanic ethnicity. JAMA Netw Open. 2023;6(4):e238214.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1974_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","volume":"16","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics. Mol Neurodegener. 2021;16(1):10.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1974_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/ane.13628","volume":"146","author":"H Zetterberg","year":"2022","unstructured":"Zetterberg H, Schott JM. Blood biomarkers for Alzheimer\u2019s disease and related disorders. Acta Neurol Scand. 2022;146(1):51\u20135.","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"1974_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12264-022-00836-7","volume":"38","author":"S Huang","year":"2022","unstructured":"Huang S, Wang YJ, Guo J. Biofluid biomarkers of Alzheimer\u2019s disease: progress, problems, and perspectives. Neurosci Bull. 2022;38(6):677\u201391.","journal-title":"Neurosci Bull"},{"key":"1974_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05219-3","author":"EMS Bandara","year":"2025","unstructured":"Bandara EMS, Asih PR, Pedrini S, Hone E, Fernando W, Martins RN. The role of glial fibrillary acidic protein in the neuropathology of Alzheimer\u2019s disease and its potential as a blood biomarker for early diagnosis and progression. Mol Neurobiol. 2025. https:\/\/doi.org\/10.1007\/s12035-025-05219-3.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"1974_CR38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3233\/JAD-230932","volume":"96","author":"Y Dong","year":"2023","unstructured":"Dong Y, Hou T, Li Y, Liu R, Cong L, Liu K, et al. Plasma Amyloid-beta, total Tau, and neurofilament light chain across the alzheimer\u2019s disease clinical spectrum: A Population-Based study. J Alzheimers Dis. 2023;96(2):845\u201358.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1974_CR39","doi-asserted-by":"publisher","first-page":"e16089","DOI":"10.1111\/ene.16089","volume":"31","author":"S Mazzeo","year":"2024","unstructured":"Mazzeo S, Ingannato A, Giacomucci G, Manganelli A, Moschini V, Balestrini J, et al. Plasma neurofilament light chain predicts alzheimer\u2019s disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study. Eur J Neurol. 2024;31(1):e16089.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1974_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14283\/jpad.2018.41","volume":"6","author":"V Perez-Grijalba","year":"2019","unstructured":"Perez-Grijalba V, Romero J, Pesini P, Sarasa L, Monleon I, San-Jose I, et al. Plasma Abeta42\/40 ratio detects early stages of alzheimer\u2019s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J Prev Alzheimers Dis. 2019;6(1):34\u201341.","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"1974_CR41","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/archneur.64.3.354","volume":"64","author":"NR Graff-Radford","year":"2007","unstructured":"Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and alzheimer disease. Arch Neurol. 2007;64(3):354\u201362.","journal-title":"Arch Neurol"},{"key":"1974_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081184","author":"A Zabala-Findlay","year":"2023","unstructured":"Zabala-Findlay A, Penny LK, Lofthouse RA, Porter AJ, Palliyil S, Harrington CR, et al. Utility of blood-based tau biomarkers for mild cognitive impairment and Alzheimer\u2019s disease: systematic review and meta-analysis. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12081184.","journal-title":"Cells"},{"issue":"2","key":"1974_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12779\/dnd.2022.21.2.59","volume":"21","author":"Y Shim","year":"2022","unstructured":"Shim Y. Clinical application of plasma neurofilament light chain in a memory clinic: a pilot study. Dement Neurocogn Disord. 2022;21(2):59\u201370.","journal-title":"Dement Neurocogn Disord"},{"key":"1974_CR44","doi-asserted-by":"publisher","first-page":"749649","DOI":"10.3389\/fnagi.2021.749649","volume":"13","author":"B Jiao","year":"2021","unstructured":"Jiao B, Liu H, Guo L, Liao X, Zhou Y, Weng L, et al. Performance of plasma amyloid beta, total Tau, and neurofilament light chain in the identification of probable alzheimer\u2019s disease in South China. Front Aging Neurosci. 2021;13:749649.","journal-title":"Front Aging Neurosci"},{"key":"1974_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111893","author":"CL Tsai","year":"2019","unstructured":"Tsai CL, Liang CS, Lee JT, Su MW, Lin CC, Chu HT, et al. Associations between plasma biomarkers and cognition in patients with Alzheimer\u2019s disease and amnestic mild cognitive impairment: a cross-sectional and longitudinal study. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8111893.","journal-title":"J Clin Med"},{"issue":"1","key":"1974_CR46","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s12877-020-01866-4","volume":"20","author":"A Slachevsky","year":"2020","unstructured":"Slachevsky A, Zitko P, Martinez-Pernia D, Forno G, Court FA, Lillo P, et al. GERO cohort Protocol, Chile, 2017\u20132022: Community-based cohort of functional decline in subjective cognitive complaint elderly. BMC Geriatr. 2020;20(1):505.","journal-title":"BMC Geriatr"},{"key":"1974_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"11","key":"1974_CR48","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134.","journal-title":"Neurology"},{"issue":"2","key":"1974_CR49","first-page":"165","volume":"31","author":"C Delgado","year":"2016","unstructured":"Delgado C, Munoz-Neira C, Soto A, Martinez M, Henriquez F, Flores P, et al. Comparison of the psychometric properties of the word and picture versions of the free and cued selective reminding test in a Spanish-Speaking cohort of patients with mild alzheimer\u2019s disease and cognitively healthy controls. Arch Clin Neuropsychol. 2016;31(2):165\u201375.","journal-title":"Arch Clin Neuropsychol"},{"issue":"6","key":"1974_CR50","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.nrl.2017.01.013","volume":"34","author":"C Delgado","year":"2019","unstructured":"Delgado C, Araneda A, Behrens MI. Validation of the Spanish-language version of the Montreal Cognitive Assessment test in adults older than 60 years. Neurologia (Engl Ed). 2019;34(6):376\u201385.","journal-title":"Neurologia (Engl Ed)"},{"issue":"3","key":"1974_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer RI, Kurosaki TT, Harrah CH Jr., Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323\u20139.","journal-title":"J Gerontol"},{"issue":"4","key":"1974_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1974_CR53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"1974_CR54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.nrleng.2019.03.009","volume":"35","author":"D Bruno","year":"2020","unstructured":"Bruno D, Slachevsky A, Fiorentino N, Rueda DS, Bruno G, Tagle AR, et al. Argentinian\/Chilean validation of the Spanish-language version of Addenbrooke\u2019s cognitive examination III for diagnosing dementia. Neurolog\u00eda (English Edition). 2020;35(2):82\u20138.","journal-title":"Neurolog\u00eda (English Edition)"},{"issue":"6","key":"1974_CR55","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000338606","volume":"33","author":"C Munoz-Neira","year":"2012","unstructured":"Munoz-Neira C, Lopez OL, Riveros R, Nunez-Huasaf J, Flores P, Slachevsky A. The technology - activities of daily living questionnaire: a version with a technology-related subscale. Dement Geriatr Cogn Disord. 2012;33(6):361\u201371.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1974_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-016-0069-4","volume":"11","author":"L Zhong","year":"2016","unstructured":"Zhong L, Xie YZ, Cao TT, Wang Z, Wang T, Li X, et al. A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. Mol Neurodegener. 2016;11:2.","journal-title":"Mol Neurodegener"},{"key":"1974_CR57","doi-asserted-by":"crossref","unstructured":"McDonald G M. Ridge regression. WIRE Comput Stat. 2009;1(1):93\u2013100.","DOI":"10.1002\/wics.14"},{"key":"1974_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2024.120636","volume":"295","author":"H Hernandez","year":"2024","unstructured":"Hernandez H, Baez S, Medel V, Moguilner S, Cuadros J, Santamaria-Garcia H, et al. Brain health in diverse settings: how age, demographics and cognition shape brain function. Neuroimage. 2024;295:120636.","journal-title":"Neuroimage"},{"issue":"1","key":"1974_CR59","doi-asserted-by":"publisher","first-page":"13984","DOI":"10.1038\/s41598-019-50315-9","volume":"9","author":"TB Chen","year":"2019","unstructured":"Chen TB, Lee YJ, Lin SY, Chen JP, Hu CJ, Wang PN, et al. Plasma Abeta42 and total Tau predict cognitive decline in amnestic mild cognitive impairment. Sci Rep. 2019;9(1):13984.","journal-title":"Sci Rep"},{"key":"1974_CR60","doi-asserted-by":"publisher","first-page":"106459","DOI":"10.1016\/j.nbd.2024.106459","volume":"193","author":"S Schraen-Maschke","year":"2024","unstructured":"Schraen-Maschke S, Duhamel A, Vidal JS, Ramdane N, Vaudran L, Dussart C, et al. The free plasma amyloid Abeta(1)(-)(42)\/Abeta(1)(-)(40) ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma Abeta(1)(-)(42)\/Abeta(1)(-)(40) ratio. The BALTAZAR study. Neurobiol Dis. 2024;193:106459.","journal-title":"Neurobiol Dis"},{"issue":"11","key":"1974_CR61","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2024-333467","volume":"95","author":"S Lehmann","year":"2024","unstructured":"Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Buee L, Blanc F, et al. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2024;95(11):1046\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1974_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255\u201363.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1974_CR63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/alz.13456","volume":"20","author":"BM Asken","year":"2024","unstructured":"Asken BM, Wang WE, McFarland K, Arias F, Fiala J, Velez-Uribe I, et al. Plasma alzheimer\u2019s biomarkers and brain amyloid in Hispanic and non-Hispanic older adults. Alzheimers Dement. 2024;20(1):437\u201346.","journal-title":"Alzheimers Dement"},{"issue":"S2","key":"1974_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/alz.091578","volume":"20","author":"WW Barker","year":"2024","unstructured":"Barker WW, Velasquez K, Loewenstein DA, Curiel RE, Armstrong MJ, Rosselli M, et al. Utility of plasma biomarkers in screening for brain amyloid in the 1Florida Alzheimer Disease Research Center (ADRC). Alzheimers Dement. 2024;20(S2):e091578.","journal-title":"Alzheimers Dement"},{"key":"1974_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1375302","volume":"15","author":"A Ingannato","year":"2024","unstructured":"Ingannato A, Bagnoli S, Mazzeo S, Giacomucci G, Bessi V, Ferrari C, et al. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia. Front Endocrinol (Lausanne). 2024;15:1375302.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1974_CR66","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s10072-023-07065-4","volume":"45","author":"S Mazzeo","year":"2024","unstructured":"Mazzeo S, Ingannato A, Giacomucci G, Bagnoli S, Cavaliere A, Moschini V, et al. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment. Neurol Sci. 2024;45(3):1031\u20139.","journal-title":"Neurol Sci"},{"issue":"8","key":"1974_CR67","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","volume":"269","author":"G Giacomucci","year":"2022","unstructured":"Giacomucci G, Mazzeo S, Bagnoli S, Ingannato A, Leccese D, Berti V, et al. Plasma neurofilament light chain as a biomarker of Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment. J Neurol. 2022;269(8):4270\u201380.","journal-title":"J Neurol"},{"key":"1974_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105937","volume":"176","author":"K Gotze","year":"2023","unstructured":"Gotze K, Vrillon A, Bouaziz-Amar E, Mouton-Liger F, Hugon J, Martinet M, et al. Plasma neurofilament light chain in memory clinic practice: evidence from a real-life study. Neurobiol Dis. 2023;176:105937.","journal-title":"Neurobiol Dis"},{"issue":"12","key":"1974_CR69","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1002\/alz.13318","volume":"19","author":"Y Yakoub","year":"2023","unstructured":"Yakoub Y, Ashton NJ, Strikwerda-Brown C, Montoliu-Gaya L, Karikari TK, Kac PR, et al. Longitudinal blood biomarker trajectories in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(12):5620\u201331.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"1974_CR70","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/jnnp-2021-326914","volume":"92","author":"D Saracino","year":"2021","unstructured":"Saracino D, Dorgham K, Camuzat A, Rinaldi D, Rametti-Lacroux A, Houot M, et al. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. J Neurol Neurosurg Psychiatry. 2021;92(12):1278\u201388.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1974_CR71","doi-asserted-by":"publisher","first-page":"e1069","DOI":"10.1212\/WNL.0000000000207581","volume":"101","author":"LAA Giannini","year":"2023","unstructured":"Giannini LAA, Seelaar H, van der Ende EL, Poos JM, Jiskoot LC, Dopper EGP, et al. Clinical value of longitudinal serum neurofilament light chain in prodromal genetic frontotemporal dementia. Neurology. 2023;101(10):e1069\u201382.","journal-title":"Neurology"},{"issue":"7","key":"1974_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050409","volume":"11","author":"AM Huaquia-Diaz","year":"2021","unstructured":"Huaquia-Diaz AM, Chalan-Davila TS, Carrillo-Larco RM, Bernabe-Ortiz A. Multimorbidity in Latin America and the Caribbean: a systematic review and meta-analysis. BMJ Open. 2021;11(7):e050409.","journal-title":"BMJ Open"},{"issue":"9","key":"1974_CR73","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/s41591-023-02495-1","volume":"29","author":"H Santamaria-Garcia","year":"2023","unstructured":"Santamaria-Garcia H, Sainz-Ballesteros A, Hernandez H, Moguilner S, Maito M, Ochoa-Rosales C, et al. Factors associated with healthy aging in Latin American populations. Nat Med. 2023;29(9):2248\u201358.","journal-title":"Nat Med"},{"issue":"10","key":"1974_CR74","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s43587-023-00490-2","volume":"3","author":"JP Ferrari-Souza","year":"2023","unstructured":"Ferrari-Souza JP, Bellaver B, Ferreira PCL, Benedet AL, Povala G, Lussier FZ, et al. APOEepsilon4 potentiates amyloid beta effects on longitudinal Tau pathology. Nat Aging. 2023;3(10):1210\u20138.","journal-title":"Nat Aging"},{"issue":"10","key":"1974_CR75","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1038\/s41380-020-0688-6","volume":"26","author":"J Therriault","year":"2021","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, et al. APOEepsilon4 potentiates the relationship between amyloid-beta and Tau pathologies. Mol Psychiatry. 2021;26(10):5977\u201388.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"1974_CR76","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/jgs.15727","volume":"67","author":"KB Rajan","year":"2019","unstructured":"Rajan KB, Barnes LL, Wilson RS, Weuve J, McAninch EA, Evans DA, Apolipoprotein E, Genotypes. Age, Race, and cognitive decline in a population sample. J Am Geriatr Soc. 2019;67(4):734\u201340.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"1974_CR77","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3233\/JAD-221167","volume":"93","author":"LKL Huggins","year":"2023","unstructured":"Huggins LKL, Min SH, Kaplan S, Wei J, Welsh-Bohmer K, Xu H. Meta-analysis of variations in association between APOE varepsilon4 and alzheimer\u2019s disease and related dementias across Hispanic regions of origin. J Alzheimers Dis. 2023;93(3):1095\u2013109.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"1974_CR78","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41582-024-00998-0","volume":"20","author":"A Ibanez","year":"2024","unstructured":"Ibanez A, Slachevsky A. Environmental-genetic interactions in ageing and dementia across Latin America. Nat Rev Neurol. 2024;20(10):571\u20132.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1974_CR79","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvado G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80(4):360\u20139.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1974_CR80","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/alz.13560","volume":"20","author":"E Sanchez","year":"2024","unstructured":"Sanchez E, Wilkinson T, Coughlan G, Mirza S, Baril AA, Ramirez J, et al. Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: results from the Ontario neurodegenerative disease research initiative. Alzheimers Dement. 2024;20(3):1753\u201370.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1974_CR81","doi-asserted-by":"publisher","first-page":"e250096","DOI":"10.1001\/jamanetworkopen.2025.0096","volume":"8","author":"SA Kim","year":"2025","unstructured":"Kim SA, Shin D, Ham H, Kim Y, Gu Y, Kim HJ, et al. Physical Activity, alzheimer plasma Biomarkers, and cognition. JAMA Netw Open. 2025;8(3):e250096.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1974_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01593-7","volume":"16","author":"K Gotze","year":"2024","unstructured":"Gotze K, Vrillon A, Dumurgier J, Indart S, Sanchez-Ortiz M, Slimi H, et al. Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study. Alzheimers Res Ther. 2024;16(1):231.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"1974_CR83","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209307","volume":"102","author":"L Grasset","year":"2024","unstructured":"Grasset L, Bouteloup V, Cacciamani F, Pellegrin I, Planche V, Chene G, et al. Associations between blood-based biomarkers and cognitive and functional trajectories among participants of the MEMENTO cohort. Neurology. 2024;102(9):e209307.","journal-title":"Neurology"},{"issue":"6","key":"1974_CR84","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1002\/alz.13829","volume":"20","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Ferreira PCL, Jacobsen E, Bellaver B, Pascoal TA, Snitz BE, et al. Association of plasma biomarkers of Alzheimer\u2019s disease and related disorders with cognition and cognitive decline: the MYHAT population-based study. Alzheimers Dement. 2024;20(6):4199\u2013211.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1974_CR85","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1002\/alz.14085","volume":"20","author":"R Gonzalez-Gomez","year":"2024","unstructured":"Gonzalez-Gomez R, Legaz A, Moguilner S, Cruzat J, Hernandez H, Baez S, et al. Educational disparities in brain health and dementia across Latin America and the united States. Alzheimers Dement. 2024;20(9):5912\u201325.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1974_CR86","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41576-019-0144-0","volume":"20","author":"D Gurdasani","year":"2019","unstructured":"Gurdasani D, Barroso I, Zeggini E, Sandhu MS. Genomics of disease risk in globally diverse populations. Nat Rev Genet. 2019;20(9):520\u201335.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"1974_CR87","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/alz.13522","volume":"20","author":"MC Dalmasso","year":"2024","unstructured":"Dalmasso MC, de Rojas I, Olivar N, Muchnik C, Angel B, Gloger S, et al. The first genome-wide association study in the Argentinian and Chilean populations identifies shared genetics with Europeans in alzheimer\u2019s disease. Alzheimers Dement. 2024;20(2):1298\u2013308.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1974_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06742-0","volume":"7","author":"M Fu","year":"2024","unstructured":"Fu M, Valiente-Banuet L, Wadhwa SS, Pasaniuc B, Vossel K, Chang TS. Improving genetic risk modeling of dementia from real-world data in underrepresented populations. Commun Biol. 2024;7(1):1049.","journal-title":"Commun Biol"},{"issue":"8","key":"1974_CR89","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","volume":"26","author":"S Dujardin","year":"2020","unstructured":"Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV, et al. Tau molecular diversity contributes to clinical heterogeneity in alzheimer\u2019s disease. Nat Med. 2020;26(8):1256\u201363.","journal-title":"Nat Med"},{"issue":"1","key":"1974_CR90","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/alz.13385","volume":"20","author":"SP Caminiti","year":"2024","unstructured":"Caminiti SP, De Francesco S, Tondo G, Galli A, Redolfi A, Perani D, et al. FDG-PET markers of heterogeneity and different risk of progression in amnestic MCI. Alzheimers Dement. 2024;20(1):159\u201372.","journal-title":"Alzheimers Dement"},{"key":"1974_CR91","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac209","author":"F Ribaldi","year":"2022","unstructured":"Ribaldi F, Rolandi E, Vaccaro R, Colombo M, Battista Frisoni G, Guaita A. The clinical heterogeneity of subjective cognitive decline: a data-driven approach on a population-based sample. Age Ageing. 2022. https:\/\/doi.org\/10.1093\/ageing\/afac209.","journal-title":"Age Ageing"},{"issue":"3","key":"1974_CR92","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/13803395.2023.2221399","volume":"45","author":"M Molina-Donoso","year":"2023","unstructured":"Molina-Donoso M, Parrao T, Meillon C, Thumala D, Lillo P, Villagra R, et al. Assessing subjective cognitive decline in older adults attending primary health care centers: what question should be asked? J Clin Exp Neuropsychol. 2023;45(3):313\u201320.","journal-title":"J Clin Exp Neuropsychol"},{"issue":"5","key":"1974_CR93","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648\u201358.","journal-title":"Ann Neurol"},{"issue":"1","key":"1974_CR94","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13195-024-01503-x","volume":"16","author":"A Orduna Dolado","year":"2024","unstructured":"Orduna Dolado A, Stomrud E, Ashton NJ, Nilsson J, Quijano-Rubio C, Jethwa A, et al. Effects of time of the day at sampling on CSF and plasma levels of alzheimer\u2019 disease biomarkers. Alzheimers Res Ther. 2024;16(1):132.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1974_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00711-1","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng X, Chen Y, Sehrawat A, Lee J, Lafferty TK, Kofler J, et al. Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting. Mol Neurodegener. 2024;19(1):40.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"1974_CR96","doi-asserted-by":"publisher","first-page":"e70032","DOI":"10.1002\/ctm2.70032","volume":"14","author":"S Baez","year":"2024","unstructured":"Baez S, Hernandez H, Moguilner S, Cuadros J, Santamaria-Garcia H, Medel V, et al. Structural inequality and Temporal brain dynamics across diverse samples. Clin Transl Med. 2024;14(10):e70032.","journal-title":"Clin Transl Med"},{"issue":"9","key":"1974_CR97","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1371\/journal.pmed.0030344","volume":"3","author":"P Perel","year":"2006","unstructured":"Perel P, Casas JP, Ortiz Z, Miranda JJ. Noncommunicable diseases and injuries in Latin America and the Caribbean: time for action. PLoS Med. 2006;3(9):e344.","journal-title":"PLoS Med"},{"issue":"1","key":"1974_CR98","volume":"14","author":"RC Vergara","year":"2022","unstructured":"Vergara RC, Zitko P, Slachevsky A, San Martin C, Delgado C. Population attributable fraction of modifiable risk factors for dementia in Chile. Alzheimers Dement Diagn Assess Dis Monit. 2022;14(1):e12273.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"7","key":"1974_CR99","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1002\/alz.13107","volume":"19","author":"JM Aravena","year":"2023","unstructured":"Aravena JM. Healthy lifestyle and cognitive aging: what is the gap behind prescribing healthier lifestyle? Alzheimers Dement. 2023;19(7):3233\u20134.","journal-title":"Alzheimers Dement"},{"issue":"10284","key":"1974_CR100","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u201390.","journal-title":"Lancet"},{"issue":"5","key":"1974_CR101","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1212\/WNL.0000000000004897","volume":"90","author":"MA Parra","year":"2018","unstructured":"Parra MA, Baez S, Allegri R, Nitrini R, Lopera F, Slachevsky A, et al. Dementia in Latin america: assessing the present and envisioning the future. Neurology. 2018;90(5):222\u201331.","journal-title":"Neurology"},{"issue":"s1","key":"1974_CR102","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.3233\/JAD-201384","volume":"82","author":"A Ibanez","year":"2021","unstructured":"Ibanez A, Parra MA, Butler C. Latin A, the Caribbean Consortium on D. The Latin America and the Caribbean Consortium on Dementia (LAC-CD): from networking to research to implementation science. J Alzheimers Dis. 2021;82(s1):S379\u201394.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1974_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-018-0915-z","volume":"18","author":"HS Choi","year":"2018","unstructured":"Choi HS, Choe JY, Kim H, Han JW, Chi YK, Kim K, et al. Deep learning based low-cost high-accuracy diagnostic framework for dementia using comprehensive neuropsychological assessment profiles. BMC Geriatr. 2018;18(1):234.","journal-title":"BMC Geriatr"},{"issue":"6","key":"1974_CR104","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"5","key":"1974_CR105","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319.","journal-title":"Nat Aging"},{"issue":"2","key":"1974_CR106","doi-asserted-by":"publisher","first-page":"e011146","DOI":"10.1136\/bmjopen-2016-011146","volume":"7","author":"L Lang","year":"2017","unstructured":"Lang L, Clifford A, Wei L, Zhang D, Leung D, Augustine G, et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. BMJ Open. 2017;7(2):e011146.","journal-title":"BMJ Open"},{"key":"1974_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.663407","volume":"12","author":"C Duran-Aniotz","year":"2021","unstructured":"Duran-Aniotz C, Orellana P, Leon Rodriguez T, Henriquez F, Cabello V, Aguirre-Pinto MF, et al. Systematic review: genetic, neuroimaging, and fluids biomarkers for frontotemporal dementia across Latin America countries. Front Neurol. 2021;12:663407.","journal-title":"Front Neurol"},{"issue":"8","key":"1974_CR108","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","volume":"14","author":"MT Ferretti","year":"2018","unstructured":"Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A, Santuccione Chadha A, et al. Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol. 2018;14(8):457\u201369.","journal-title":"Nat Rev Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-01974-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01974-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01974-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:02:52Z","timestamp":1774886572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-01974-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1974"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-01974-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was approved by the Ethics Committee of the Servicio de Salud Metropolitano Oriente (SSMO), Santiago (Chile), institution number IORG0006407. All participants had the capacity to provide informed consent in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TKK has consulted for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., and Alzheon, has served on advisory boards for Siemens Healthineers and Neurogen Biomarking LLC., outside the submitted work. He has received in-kind research support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, as well as meeting travel support from the Alzheimer\u2019s Association and Neurogen Biomarking LLC., outside the submitted work. TKK has received royalties from Bioventix for the transfer of specific antibodies and assays to third party organizations. He has received honoraria for speaker\/grant review engagements from the NIH, UPENN, UW\u2010Madison, the Cherry Blossom symposium, the HABS-HD\/ADNI4 Health Enhancement Scientific Program, Advent Health Translational Research Institute, Brain Health conference, Barcelona\u2010Pittsburgh conference, the International Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec Center for Drug Discovery, Canada, all outside of the submitted work. TKK is an inventor on several patents and provisional patents regarding biofluid biomarker methods, targets and reagents\/compositions, that may generate income for the institution and\/or self should they be licensed and\/or transferred to another organization. These include WO2020193500A1: Use of a ps396 assay to diagnose tauopathies; US 63\/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer\u2019s Disease Patients; US 63\/672,952: Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer\u2019s Disease; US 63\/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric tau and soluble tau aggregates. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}